We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
IRLAB-A.ST

Price
6.98
Stock movement up
+0.16 (2.35%)
Company name
IRLAB Therapeutics AB (publ)
Exchange
(ST
,
Currency
SEK
)
Sector
Healthcare >
Biotechnology
Market cap
361.48M
Ent value
393.36M
Price/Sales
7.14
Price/Book
9.51
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
12.48%
1 year return
-61.22%
3 year return
-43.48%
5 year return
-13.91%
10 year return
-
Last updated: 2025-03-26

DIVIDENDS

IRLAB-A.ST does not pay dividends or no data was received

VALUATION

Valuation Ratios

Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Valuation (Sales/Book Value) data
Price to Sales7.14
Price to Book9.51
EV to Sales7.77

FINANCIALS

Per share

Per share data
Current share count51.79M
EPS (TTM)-2.17
FCF per share (TTM)-1.49

Income statement

Income statement data
Revenue (TTM)50.62M
Gross profit (TTM)-82.96M
Operating income (TTM)-111.83M
Net income (TTM)-112.72M
EPS (TTM)-2.17
EPS (1y forward)-0.13

Margins

Margins data
Gross margin (TTM)-163.91%
Operating margin (TTM)-220.94%
Profit margin (TTM)-222.69%

Balance Sheet

Please create a free account or log in to access this chart
Balance Sheet data
Cash90.38M
Net receivables12.13M
Total current assets102.51M
Goodwill0.00
Intangible assets46.86M
Property, plant and equipment0.00
Total assets160.29M
Accounts payable61.98M
Short/Current long term debt60.29M
Total current liabilities117.88M
Total liabilities122.26M
Shareholder's equity38.03M
Net tangible assets0.00

Cash flow

Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-76.89M
Capital expenditures (TTM)199.00K
Free cash flow (TTM)-77.09M
Dividends paid (TTM)0.00

Financial returns

Please create a free account or log in to access this chart
Financial returns data
Return on Equity-296.40%
Return on Assets-70.32%
Return on Invested Capital-120.00%
Cash Return on Invested Capital-82.07%

STOCK INFORMATION

Stock chart

Stock price data
Open6.80
Daily high6.98
Daily low6.46
Daily Volume64K
All-time high104.95
1y analyst estimate56.07
Beta0.66
EPS (TTM)-2.17
Dividend per share-
Ex-div date-
Next earnings date6 May 2025

Downside potential

Downside potential data
IRLAB-A.STS&P500
Current price drop from All-time high-93.35%-6.11%
Highest price drop-95.85%-56.47%
Date of highest drop6 Mar 20259 Mar 2009
Avg drop from high-55.62%-11.07%
Avg time to new high41 days12 days
Max time to new high1440 days1805 days
COMPANY DETAILS
IRLAB-A.ST (IRLAB Therapeutics AB (publ)) company logo
Marketcap
361.48M
Marketcap category
Small-cap
Description
IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 research programs for the treatment of neurodegenerative disorders and ageing; IRL1117, a drug candidate developed for once-daily oral treatment for the hallmark symptoms of Parkinson's; and IRL757 to treat apathy in neurological diseases. In addition, the company develops P003, a research project that develops drugs for the treatment of newly diagnosed Parkinson's disease. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is headquartered in Gothenburg, Sweden.
Employees
32
Website
https://www.irlab.se
Investor relations
-
SEC filings
IRLAB-A.ST SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
UNDERSTAND THE BUSINESS
COMPANY NEWS
All newsPress releases
No items found
Disclaimer
Skyfall Technology OÜ assumes no responsibility or liability for any errors or omissions in the content of this site. The information contained in this site is provided on an “as is” basis with no guarantees of completeness, accuracy, usefulness or timeliness. Please also note, that any action you take upon the information provided on this website is strictly at your own risk. This website is intended to be used and must be used for informational purposes only and you should take independent financial advice from a professional and independently research and verify everything you see on the site.
Menu
HomePortfolio ManagementCompany ScreenerGreen InvestmentExchangesContact Us
Language
ENHUNOSVDAFIESDENLFRITPTPLCSSKROELTRRUAF
© 2024 Skyfall Technology OÜ All Rights Reserved